Point Mutation Cell Models From $7480

Home > Promotions > Point Mutation Cell Models From $7480
Back-To-School Sale | Point Mutation Cell Models From $7480
Ubigene's CRISPR-U™ technique / Red Cotton™ PM Strategy Design System / 4 solutions like RNP
Three keys to improve editing efficiency by 10X, easily cope with the chanllenge of tricky sites
Success modified cell lines cover 8 major fields including lung, liver, colon cancers, etc
Deliver homozygous clones as fast as 8 weeks
Point Mutation Cell Custom Service
icon1.png
Ubigene’s CRISPR-U™ technique
icon2.png
Red Cotton™ PM Strategy Design System
icon3.png
4 solutions like RNP
From $7480 Deliver homozygous clones
Consults with our technical support
Point Mutation Cell
Custom Service
icon1.png
Ubigene’s CRISPR-U™ technique
icon2.png
Red Cotton™ PM Strategy Design System
icon3.png
4 solutions like RNP
From $7480
Deliver homozygous clones
Consults with our technical support
Knock-In Cell Custom Service
icon4.png
In situ fluorescence KI
icon5.png
In situ fusion of tag
icon6.png
Safe harbor KI
From $9680 Deliver positive clones
Consults with our technical support
Knock-In Cell Custom
Service
icon4.png
In situ fluorescence KI
icon5.png
In situ fusion of tag
icon6.png
Safe harbor KI
From $9680
Deliver positive clones
Consults with our technical support
Popular and Success Modified Cell Lines
Popular and Success
Modified Cell Lines
icon7.png icon7.png 300+ Cell Line
icon8.png icon8.png 6000+ Success Cases
Partial List
Lung cancer A549 MSTO-211H NCI-H1975
Lung cancer Hep G2 Hepa 1-6 MHCC97-H
Breast cancer MDA-MB-231 4T1 E0771
Colon cancer HCT 116 MC38 NCI-H1975 CT26.WT
Leukemia Jurkat, Clone E6-1 K-562 RAW 264.7 THP-1
Glioma U-87 MG LN-229 GL261 T98G
Partial List
Lung cancer A549 MSTO-211H NCI-H1975
Lung cancer Hep G2 Hepa 1-6 MHCC97-H
Colon cancer HCT 116 MC38 NCI-H1975 CT26.WT
Breast cancer MDA-MB-231 4T1 E0771
Leukemia Jurkat, Clone E6-1 K-562 RAW 264.7 THP-1
Glioma U-87 MG LN-229 GL261 T98G
Promotion period: 2024.9.19-2024.10.15
Promotion for academics only.
Note: The selection and classification of popular cell lines in this event are based on relevant public information and project experience, for reference only. Ubigene reserves the right to the ultimate interpretation.
×

Subscribe Us

By subscription, you consent to allow Ubigene Biosciences to store and process the information provided above to deliver the latest news, research spotlight, and promotions. You can unsubscribe from these communications at anytime.
×

Search documentation

Literature:

Name: *

Company: *

Telephone: *

Email:

Notes: After submitting the order, we will contact you as soon as possible.

request now